Conjuntivitis alérgica

Epinastina 0,05% como tratamiento de la conjuntivitis alérgica

El presente estudio tiene la finalidad de evaluar el mecanismo de acción, la eficacia, tolerabilidad y seguridad de la epinastina 0,05% para el tratamiento de la conjuntivitis alérgica.

Autor/a: William B. Trattler, MD; Jodi Luchs, MD; Parag Majmudar, MD

Fuente: Elestat (Epinastina HCI Ophthalmic Solution 0,05%) as Therapeutic for Allergic Conjunctivitis. Clin Ther 2004; 26:35-47

Indice
1. Bibliografía
2. Desarrollo

1. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy.J Allergy Clin Immunol. 2000;106:1019–1032.
2. Raizman MB. Recognizing and treating ocular allergy in women. Female Patient. 2003;28:14–19.
3. Wuthrich B, Brignoli R, Canevascini M, et al. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr. 1998;128:139–143.
4. Klein B, Schmit-Eilenberger V, Schwalbe C, et al. Eye allergy symptoms have negative impact on patients’ activities and emotions. Poster presented at Annual Meeting of the American Academy of Ophthalmology (AAO), November 15–18, 2003, Anaheim, CA.
5. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2006;117:S450–S456. Elestat as a Therapeutic for Allergic Conjunctivitis ’ 97
6. McGill JI, Holgate ST, Church MK, et al. Allergic eye disease mechanisms.
Br J Ophthalmol. 1998;82:1203–1214.

Síntesis y traducción: Dr. Martín Mocorrea, editor responsable de Intramed en la especialidad de oftalmología.